Northwell Announces Affiliation Agreement With Acclaimed Orthopedic Institute

NEW HYDE PARK, N.Y., April 20, 2017 /PRNewswire-USNewswire/ — Northwell Health has signed a strategic affiliation agreement with the Rothman Institute, one of the nation’s largest, most-prestigious orthopedic practices.

Headquartered in Philadelphia, Pennsylvania, Rothman Institute is known internationally as a preeminent orthopedic and musculoskeletal practice, with more than 25 locations throughout Pennsylvania and New Jersey, including two orthopedic urgent care clinics.  Rothman Institute is recognized for their innovative treatment methods, research, education and technology.

The Northwell Health Orthopaedic Institute will be working with Rothman Institute to develop centers of excellence for orthopedic care in the New York Metropolitan area, including Manhattan.

“We’re excited about the affiliation with the Rothman Institute,” said Nicholas Sgaglione, MD, chair of orthopedics at Northwell Health. “The affiliation will bring together two nimble, forward-thinking organizations that emphasize high-quality care. We also look forward to working with the Rothman Institute to co-brand various marketing initiatives, the ongoing recruitment of top-level physicians, joint research, and tracking and measuring patient outcomes.”

“We look forward to joining the Northwell Health family,” said Alexander R. Vaccaro, MD, PhD, MBA, president of Rothman Institute, Richard H. Rothman Professor and chairman of the Department of Orthopaedics, and professor of neurosurgery at Thomas Jefferson University and Hospitals. “This agreement expands Rothman Institute’s footprint into New York City and the surrounding suburbs. We are looking forward to bringing our excellent musculoskeletal care to Northwell Health’s communities and patients now and for years to come.”

About Northwell Health
Northwell Health is New York State’s largest health care provider and private employer, with 21 hospitals and over 550 outpatient practices. We care for more than two million people annually in the metro New York area and beyond, thanks to philanthropic support from our communities. Our 61,000 employees – 15,000+ nurses and nearly 3,400 physicians, including nearly 2,700 members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institute. We’re training the next generation of medical professionals at the visionary Hofstra Northwell School of Medicine and the School of Graduate Nursing and Physician Assistant Studies. And we offer health insurance through CareConnect. For information on our more than 100 medical specialties, visit Northwell.edu.

About Rothman Institute
Rothman Institute is a private orthopaedic practice dedicated to providing communities with high-quality, compassionate, and affordable musculoskeletal care that is grounded in evidence-based medicine, the results of which will exceed expectations. Rothman Institute orthopaedists treat patients at over 25 locations in the Philadelphia-region, including orthopaedic urgent care clinics in Marlton, NJ and Limerick, PA.

With experts in orthopaedic sub-specialties including spine, hip and knee, foot and ankle, shoulder and elbow, hand and wrist, sports medicine, physical medicine and  rehabilitation, orthopaedic oncology and trauma, Rothman Institute is internationally recognized for excellence in clinical treatment  methods, research, education and technology. Consistently recognized as national and regional “Top Docs,” Rothman Institute is proud to be the first practice serving as official team physicians for all four of the major professional sports teams in one city, the Philadelphia Eagles, Phillies, Flyers and 76ers, as well as over 40 college and high school teams. For more information about Rothman Institute please call 1-800-321-9999 or visit www.RothmanInstitute.com.

SOURCE Northwell Health

Related Links

https://www.northwell.edu

Ambulatory Services Market is Expected to Reach 2455.2 Billion by 2022 at a CAGR of 4.7%

PUNE, India, April 20, 2017 /PRNewswire/ — Market Research Future published a half-cooked research report on Global Ambulatory Services Market. The Global Market for Ambulatory Services is growing continuously and expected to grow at a CAGR of 4.7% from 2014 to 2022

Market Highlights

The Global Ambulatory Services Market has been evaluated as steadily growing market and it is expected that the market will continue to grow similarly in the near future. Ambulatory services provides cost efficient and convenient healthcare facilities to the patient. Appropriate ambulatory care reduce the chances of impatient care or reduces chances of hospitalization. Ambulatory care is also known as outpatient care which provides different healthcare facilities such as consultation, observation, diagnosis, treatment, rehabilitation services. In ambulatory surgery center, patient need not to admit to the hospital and treatment is done outside the hospital premises.

Ambulatory surgery centers segmented on the basis of types which consist Hospital emergency departments (EDs), Primary care offices, Hospital-based outpatient departments (OPDs), physician private practices, Community Health Centers, Ambulatory surgery centers (ASCs), Urgent Care Centers, and Others. Primary care office segment is growing rapidly and it holds largest market share in ambulatory market. Ambulatory surgery center provides many affordable healthcare services such as pain management, orthopedic, ophthalmology, dermatology, gastroenterology, and others. Government initiative to overcome high healthcare cost and provide affordable medical facilities are driving the growth for ambulatory services market. Increasing aging population and chronic diseases are also major factors which leading the growth for the market. Global Ambulatory Services Market is expected to reach USD 2455.2 billion by 2022 at a CAGR of 4.7%.

North America is the largest market for Ambulatory Services and expected to grow significant rate during the forecast period. Europe is the second largest market for Ambulatory Services and expected to grow steadily during forecasting period. Due to improving healthcare infrastructure and government initiative to provide affordable healthcare facilities in Asia-Pacific region, the market for ambulatory services is expected to grow significantly during the forecast period.

Request a Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/2491

Global Ambulatory Services Market Players:

  • AmSurg Corp. (US),
  • Surgical Care Affiliates (US),
  • Surgery Partners (US),
  • SurgCenter (US),
  • Symbion Inc. (US),
  • Hospital Corporation of America (HCA)
  • Holding (US),
  • Healthway Medical Corporation Limited (Singapore),
  • HCA Holdings, Inc. (US)

Market Segmentation:

Ambulatory Services market has been segmented on the basis of product type which comprises of Hospital emergency departments (EDs), Primary care offices, Hospital-based outpatient departments (OPDs), physician private practices, Community Health Centers, Ambulatory surgery centers (ASCs), Urgent Care Centers, and Others.

Access Report Details @ https://www.marketresearchfuture.com/reports/ambulatory-services-market-2491

Regional Analysis:

Depending on geographic region, Ambulatory Services market is segmented into four key regions: Americas, Europe, Asia-Pacific, and Middle East & Africa. Considering the global scenario of the market, North America comprise largest market share in global Ambulatory Services market. Moreover the European market is also growing continuously. On the other hand, Asia-Pacific market is expected to grow at the significant rate in the Ambulatory Services market segment during the forecasted period. Rest of the World is likely to have a limited but steady growth in the market.

Browse Related Report

Wearable Sensors Market Information, by Types (Motion Sensors, Medical Based Sensors, Image sensors, Position Sensors, Pressure Sensors, Inertial Sensors and Others), by Application (Smart Wristwear, Smart Glasses, Smart Bodywears, Smart Footwear and Other Wearable Devices) by End User (Consumer, Healthcare, Enterprise and Industrial and Others) – Forecast to 2020

https://www.marketresearchfuture.com/reports/wearable-sensors-market

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact
Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

SOURCE Market Research Future

Related Links

https://www.marketresearchfuture.com

Anika to Issue First-Quarter 2017 Financial Results and Business Highlights on Wednesday, May 3

April 19, 2017

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2017 financial results after the close of the market on Wednesday, May 3, 2017 and to hold a conference call the next day, Thursday, May 4, 2017, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook.

The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the “Investor Relations” section of Anika’s website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST®, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

Contacts

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer
or
For Media Inquiries:
Pure Communications, Inc.
Katie Engleman, 910-509-3977

Mazor Robotics to Report First Quarter Financial Results on May 10, 2017

April 20, 2017

CAESAREA, Israel–(BUSINESS WIRE)–Mazor Robotics Ltd. (TASE:MZOR; NASDAQGM:MZOR), a pioneer and a leader in the field of surgical guidance systems, announced today that it will report financial results for the first quarter ended March 31, 2017, before the U.S. markets open on Wednesday, May 10, 2017.

The company will host a conference call to discuss these results on Wednesday, May 10, 2017, at 8:30 AM ET (3:30 PM IST). Investors within the United States interested in participating are invited to call 888-298-3457. Participants in Israel can use the toll-free dial-in number 1 80 924 5906. All other international participants can use the dial-in number 719-457-2689. For all callers, refer to Conference ID 8737181.

A replay of the event will be available for two weeks following the conclusion of the call. To access the replay, callers in the United States can call 1-866-375-1919 and reference the Replay Access Code: 8737181. All international callers can dial +1 719-457-0820, using the same Replay Access Code. To access the webcast, please visit www.mazorrobotics.com and select ‘Investor Relations.’

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit www.MazorRobotics.com.

Contacts

U.S. Contacts:
EVC Group
Investors
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
Doug Sherk, 415-652-9100
dsherk@evcgroup.com
or
Financial Media Contact
Tom Gibson, 201-476-0322
tom@tomgibsoncommunications.com

InVivo Therapeutics Announces Oral Presentations at the 2017 American Spinal Injury Association Annual Scientific Meeting

April 20, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be giving two oral presentations at the 2017 American Spinal Injury Association (ASIA) Annual Scientific Meeting to be held April 26-29, 2017 in Albuquerque, New Mexico. Alex Aimetti, Ph.D., Vice President, Medical Education and Scientific Support, will present a clinical trial update during the “Clinical Trials 360-degree” session sponsored by Spinal Cord Outcomes Partnership Endeavor (SCOPE) on Friday, April 28. Dr. Aimetti will also present an abstract entitled “Relationship of ASIA Impairment Scale (AIS) Grade to Post-injury Hospitalization Costs in Thoracic Spinal Cord Injury” during a general session on Saturday, April 29. The abstract is co-authored by Dr. Aimetti, Ellen Dukes, Ph.D., Steven Kirshblum, M.D., Sarah Qin, M.B.A., Rebecca Bornheimer, B.A., and Gerry Oster, Ph.D. In addition to the two oral presentations, the company will have an exhibit booth at the meeting.

Mark Perrin, Chairman and CEO, said, “The American Spinal Injury Association Annual Scientific Meeting will allow us to continue to strengthen and expand our relationships within the spinal cord injury research and care network, and we look forward to having a significant presence at this meeting. We are also pleased to be providing an update on our clinical program, especially given our significant progress throughout the start of this year.”

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in The INSPIRE Study for the treatment of patients with acute, complete (AIS A), thoracic traumatic spinal cord injury and a pilot study for acute, complete (AIS A), cervical (C5-T1) traumatic spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffoldreceived the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold and the progress of the clinical program. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2016, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

Contacts

InVivo Therapeutics Holdings Corp.
Heather Hamel, 617-863-5530
Investor Relations
Investor-relations@invivotherapeutics.com

RTI Surgical® Schedules 2017 First Quarter Earnings Call for April 27, 2017

April 20, 2017

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the first quarter 2017 on Thursday, April 27, 2017, prior to the market open.

RTI will host a conference call and simultaneous audio webcast to discuss first quarter results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International). The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on RTI’s website for one month following the call.

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

Contacts

RTI Surgical Inc.
Robert Jordheim
Chief Financial Officer
rjordheim@rtix.com
or
Roxane Wergin, 386-418-8888
Director, Corporate Communications
rwergin@rtix.com

Oxford Finance Provides $20 Million Senior Debt Facility to Cerapedics Inc.

ALEXANDRIA, Va. and WESTMINSTER, Colo., April 19, 2017 /PRNewswire/ — Oxford Finance LLC (“Oxford”), an industry-leading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $20 million senior secured term loan with Cerapedics Inc. (“Cerapedics”) a privately-held orthobiologics company engaged in the development and commercialization of bone graft substitute products for the treatment of orthopedic injuries.

Cerapedics’ lead product, i-FACTOR Peptide Enhanced Bone Graft, is the only biologic bone graft that uses a unique small peptide attachment factor (P-15) bound to anorganic bone mineral (ABM). The i-FACTOR is the first and only FDA-approved product for Anterior Cervical Discectomy and Fusion (ACDF) and is the first device to demonstrate superiority versus autograft.

Loan proceeds are being used to support the ongoing commercialization of i-FACTOR’s use in cervical spine procedures and help fund a FDA study on its application in Transforaminal Lumbar Interbody Fusion (TLIF.)

“We are encouraged by the strength of i-FACTOR’s clinical safety and efficacy data,” said Christopher A. Herr, senior managing director at Oxford Finance. “Oxford is pleased to provide capital to help Cerapedics continue to enhance the science of bone repair.”

“We are pleased to be working with a strong partner in Oxford Finance in executing on our key growth initiatives,” said Glen Kashuba, chief executive officer of Cerapedics.

About Oxford Finance LLC

Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. Oxford has originated over $4 billion in loans, with credit facilities ranging from $5 million to $100 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in San Diego, California; Palo Alto, California; Salt Lake City, Utah and the greater Boston area. For more information, visit oxfordfinance.com.

About Cerapedics Inc.

Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found at cerapedics.com.

Media Contacts:

Amanda Stern 

Troy Wilford

Oxford Finance LLC 

Cerapedics Inc.

Tel: (888)471-0174 

Tel: (484)247-8054

astern@oxfordfinance.com 

twilford@cerapedics.com

 

SOURCE Oxford Finance Corporation

Related Links

http://www.oxfordfinance.com

NuVasive Launches New Spinal Trauma Portfolio

SAN DIEGO, April 19, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the launch of the new RELINE® Trauma portfolio, which will serve as the Company’s foundation to address the estimated $100 million U.S. spine trauma fixation market, currently growing 5.6 percent annually.

Spine trauma cases are performed approximately 90 percent open and only 10 percent minimally-invasive. RELINE Trauma is the first trauma system designed to provide surgeons the flexibility to customize their approach intra-operatively, including traditional open, MAS® (Maximum Access Surgery) or hybrid procedures, depending on the pathology and patient needs. Developed by the leader in minimally disruptive spine technology, the Company’s new trauma system supports surgeons in the increasing transition from open to MAS spine procedures.

The system offers surgeons the ability to customize implant types and supports a multitude of techniques, depending on surgeon preference. Also, RELINE Trauma enhances the surgeon’s ability to dial-in fracture correction through a dual rack system achieving independent lordosis restoration and parallel compression/distraction for ligamentotaxis. This enables procedures to be completed by one surgeon rather than two, helping reduce the total cost of the procedure.

“The versatility of the new RELINE Trauma system allows me to address trauma surgery circumferentially,” said Juan Uribe, M.D., Associate Professor, Department of Neurosurgery, University of South Florida College of Medicine, Tampa, Florida. “NuVasive has removed the need for a second surgeon and eliminated hours in comparison to the alternative technique. RELINE Trauma is a game-changer in spine.”

In addition, the RELINE Trauma Fracture Frame instrumentation allows for controlled fracture correction throughout the procedure, with or without a rod present in the construct. The systems also allows surgeons the ability to place various rod diameters and/or materials before or after fracture correction, greatly improving the ability to reduce fractures more easily and reproducibly.

“The launch of RELINE Trauma is a key milestone in our continued commitment to industry-leading innovation that delivers untapped clinical and economic value for our surgeon partners,” said Jason Hannon, president and chief operating officer of NuVasive. “RELINE Trauma will help define the standard of trauma care for spine, with its ability to dramatically reduce time and provide complete versatility intra-operatively. The system will be the foundation of our trauma portfolio as we invest further in this key market.”

RELINE Trauma is further integrated with proprietary NuVasive Computer Assisted Technologies such as NVM5®, NuvaLine™, NuvaMap® and NuvaMap® O.R., all within the Integrated Global Alignment® (iGA) platform. iGA allows surgeons to calculate, correct and confirm spinal alignment through preoperative planning, intraoperative assessment, and postoperative confirmation for their trauma cases. Additionally, constructs are further enhanced with the integration of the Bendini® system which expedites manual rod manipulation via computer-assisted bend instructions.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Life Spine Announces FDA Clearance of PLATEAU®-C Ti Cervical Spacer System

April 19, 2017

HUNTLEY, Ill.–(BUSINESS WIRE)–Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that the U.S. Food and Drug Administration (FDA) has given 510(k) market clearance to the PLATEAU-C Ti Cervical Spacer System.

PLATEAU-C Ti joins Life Spine’s extensive portfolio of 62 product lines cleared by the FDA. The system offers Life Spine’s proprietary titanium surface technology, OSSEO-LOC, which is an innovative surface technology that helps create an environment for potential bone growth. Additionally, in comparison to its PEEK counter-part, PLATEAU-C Ti offers additional graft windows for increased visibility in-situ and bone graft containment.

“The new PLATEAU-C Ti with OSSEO-LOC surface technology makes a great addition to an already robust interbody portfolio which includes PEEK, titanium, expandable and stand-alone technologies. As one of the fastest-growing, most innovative companies in our space it is important to our surgeons and patients that we continue to advance the cutting edge of technology,” said Mariusz Knap, Vice President of Marketing for Life Spine.

PLATEAU-C Ti entered a Full Market Release on April 3, 2017.

About Life Spine

Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.lifespine.com.

Life Spine is a registered trademark.

Contacts

Life Spine
Mr. Omar Faruqi
Chief Financial Officer
ofaruqi@lifespine.com
847-884-6117

Life Spine Announces AANS 2017 Attendance and Product Spotlights

April 19, 2017

HUNTLEY, Ill.–(BUSINESS WIRE)–Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, is pleased to announce its participation at the American Association of Neurosurgical Surgeons (AANS) Annual Meeting, April 22-26 in Los Angeles, CA, at Booth #1857. The meeting is expected to attract over 3,500 neurosurgeons and other healthcare professionals from across the globe.

Life Spine continues to focus on transforming procedurally based surgical solutions by showcasing the innovative PLATEAU®-C Ti Cervical Spacer System, PROLIFT® Expandable Interbody and the 2016 Spine Technology Award-Winning LONGBOW® Expandable Lateral Spacer platforms.

PLATEAU-C Titanium joins Life Spine’s extensive portfolio of 62 product solutions cleared by the FDA, and was commercially launched April 3rd, 2017.

PROLIFT is a best-in-class expandable interbody which allows for in-situ disc height restoration for micro-invasive PLIF, TLIF or oblique approach. PROLIFT, in conjunction with CENTERLINE® Midline Screws and CALYPSO™ Posterior Retractor System, allows for minimal tissue and muscle distraction with a 3mm bulleted tip and height increase from 8mm-16mm from initial insertion to full expansion.

LONGBOW Expandable Lateral Spacer System, when used with the CENTRIC® Lateral Retractor System, allows for the potential reduction of nerve damage and post-operative complications. These systems were designed to work together to minimize the amount of psoas and lumbar plexus retraction up to 45% during a lateral procedure. LONGBOW also simplifies insertion of bone graft, up to 11cc, post-expansion.

About Life Spine

Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.lifespine.com.

Life Spine is a registered trademark.

Contacts

Life Spine
Mr. Omar Faruqi
Chief Financial Officer
ofaruqi@lifespine.com
847-884-6117